With global healthcare under unprecedented pressure, innovation must accelerate like never before. Population increase, rising life expectancy, urbanisation and the spread of infectious diseases demand a new frontier for bioscience innovation to ensure the right medicines are developed when the world needs them most. The iQ Group Global is proud to share the launch of […]

The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) has commenced engagement with the US Food and Drug Administration (FDA) for the approval pathway of the Saliva Glucose Biosensor. On May 1st, LSBD lodged a 513(g) submission, the first step to seeking regulatory approval for a device with […]

In our series ‘COVID-19 Explained’, experts from The iQ Group Global demystify frequently asked questions about the COVID-19 virus.   This week, CRC and Farmaforce Chief Scientific Officer Athena Kolivos explains the difference between a vaccine and an antibody test, and why both are important in the fight against the COVID-19 pandemic.  What is a vaccine and […]

The below article was produced by The University of Texas at Austin and republished here with permission. UNIVERSITY OF TEXAS AT AUSTIN – A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects […]

The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, announced that Dr. Jonathan Arambula will join The iQ Group Global as the Vice President of Research, OncoTEX Inc. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its novel anticancer drug platform, TEX […]

One of the world’s most renowned Chemists and co-founder of the biopharmaceutical company, Pharmacyclics, Professor Jonathan L. Sessler has been appointed as a Non-Executive Director to the board of OncoTEX Inc., it was announced today. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its […]

SYDNEY –  The iQ Group Global has announced its equity crowd-sourced funding platform Capital Labs has launched a new investment offer, driving a new era in Australian Healthcare. One of the first ASIC authorised equity crowd-sourced funding (CSF) platforms in Australia, Capital Labs only partners with companies launching technology and innovations that have a positive […]

FarmaForce has set a new standard for sales excellence after being recognised as Sales Team of the Year for the fourth consecutive year at the 15th annual PRIME Awards. The FarmaForce Nephrology Specialist Team, an Otsuka Australia and FarmaForce strategic partnership, won the 2019 Sales Team of the Year award for exceptional sales, excellence in […]

The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, today announced it has added a novel anticancer drug platform to its portfolio that has the ability to develop a range of cancer therapeutics. TEX Core is an anticancer drug platform that has the ability to develop a range of well-tolerated, MRI-detectable […]

Morningstar have recently released quantitative research reports on two iQGG ASX-listed companies: iQ3 Corp (ASX:IQ3) FarmaForce (ASX:FFC)